These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30075504)

  • 1. Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis.
    Xing J; Yin X; Chen D
    Medicine (Baltimore); 2018 Aug; 97(31):e11384. PubMed ID: 30075504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
    Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
    Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
    Nicklaus MD; Ludwig SL; Kettle JK
    J Oncol Pharm Pract; 2018 Apr; 24(3):185-189. PubMed ID: 29284351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Rutjes AW; Porreca E; Candeloro M; Valeriani E; Di Nisio M
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD008500. PubMed ID: 33337539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
    Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
    Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
    Cao YB; Zhang JD; Shen H; Jiang YY
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1099-108. PubMed ID: 20812009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis.
    Huang HF; Li SS; Yang XT; Xie Q; Tian XB
    Medicine (Baltimore); 2018 Nov; 97(48):e13465. PubMed ID: 30508972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
    Patel AA; Ogden K; Mody SH; Bookhart B
    J Med Econ; 2015 May; 18(5):323-32. PubMed ID: 25557176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial :
    Longo de Oliveira ALM; de Oliveira Pereira RF; Agati LB; Ribeiro CM; Kawamura Suguiura GY; Cioni CH; Bermudez M; Pirani MB; Caffaro RA; Castelli V; Resende Aguiar VC; Volpiani GG; Paschoa A; Scarlatelli Macedo AV; de Barros E Silva PGM; de Campos Guerra JC; Fareed J; Lopes RD; Ramacciotti E
    Clin Appl Thromb Hemost; 2022; 28():10760296221132556. PubMed ID: 36474344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
    Signorelli JR; Gandhi AS
    J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty.
    Charters MA; Frisch NB; Wessell NM; Dobson C; Les CM; Silverton CD
    J Arthroplasty; 2015 Jul; 30(7):1277-80. PubMed ID: 25724111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
    Loke YK; Kwok CS
    J Clin Pharm Ther; 2011 Feb; 36(1):111-24. PubMed ID: 21198726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis.
    Farey JE; An VVG; Sidhu V; Karunaratne S; Harris IA
    Orthop Traumatol Surg Res; 2021 Feb; 107(1):102606. PubMed ID: 32631716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.
    Trkulja V; Kolundzic R
    Croat Med J; 2010 Apr; 51(2):113-23. PubMed ID: 20401953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
    Lee JH; Oh YM; Lee SD; Lee JS
    J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.
    Yoshida Rde A; Yoshida WB; Maffei FH; El Dib R; Nunes R; Rollo HA
    Ann Vasc Surg; 2013 Apr; 27(3):355-69. PubMed ID: 23351997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Utility of Rivaroxaban as Primary Venous Thromboprophylaxis in an Adult Trauma Population.
    Kingdon LK; Miller EM; Savage SA
    J Surg Res; 2019 Dec; 244():509-515. PubMed ID: 31336243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
    Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.